Separate names with a comma.
Atai Therapeutics discovers new 5-HT2A receptor partial agonists July 16, 2025 Atai Therapeutics Inc. has synthesized new tetrahydro...
List of Patent Activity on 2025 for MindMed US20250205196 – Formulations of Psilocin with Enhanced Stability Jurisdiction: United States...
This company will possibly acquire $ATAI, $MNMD and or $CMPS very very soon.
$ATAI$JNJ reported Q2 2025 sales of $414 million for SPRAVATO (esketamine), marking a 53% year-over-year increase—this momentum is driven by...
$ATAI J&J doesn't have to 'do deals out of desperation' despite facing patent cliffs: CFO...
$MNMD J&J doesn't have to 'do deals out of desperation' despite facing patent cliffs: CFO...
RFK Jr. and other Trump officials embrace psychedelics after FDA setback...
Sekur Private Data Ltd. (OTCQB: SWISF | CSE: SKUR) [MEDIA] Sekur (SWISF | SKUR) is a privacy-first communication platform based in Switzerland...
MAPS supporting MM-120 Trial - Poston Instagram. I would say this is big. https://www.instagram.com/p/DL-eltENqfw/?igsh=bzJscXQ4NzVyMzl1
Hope for Depression and Other Diagnoses with Psychedelics - Psychology Today...
See the pitch deck a psychedelics startup just used to raise $18.6 million to develop new treatments derived from the Sonoran Desert toad...
Massive catalysts ahead... [IMG]
It is time for a move higher in biotech, says Mizuho's Jared Holz [MEDIA]
CTIS 2025: Automated Assessment Auditing Across MindMed’s Pivotal Programs [MEDIA] Presentedy by: Dan Karlin, Chief Medical Officer, MindMed
atai Life Sciences – Strong Phase 2b topline data for BPL-003 (5-MeO-DMT) and further strategic backing atai announced very strong Phase 2b...
Strong Phase 2b results for psychedelic-based treatment BPL-003 (a nasal spray version of mebufotenin / 5-MeO-DMT) for treatment-resistant...
atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant...
Driven by a desire to help ex-servicemembers with mental illness, GOP lawmakers led a failed campaign last year to persuade the Biden...
